- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01706692
Swiss Dermatology Network of Targeted Therapies (SDNTT) (SDNTT)
Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy.
The registry will also evaluate safety clinical outcomes and health related quality of life.
Study Overview
Status
Conditions
Detailed Description
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) in Switzerland is largely performed with systemic therapies. This includes conventional systemic therapy such as fumaric acids, methotrexate, cyclosporin A, retinoids, systemic PUVA, Acitretin and biological treatments such as etanercept, infliximab, adalimumab and within a pre-registration program ustekinumab. While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. SDNTT, the Swiss registry on the treatment of moderate to severe Pso and PsA documents the long-term course of patients being administered a defined biologic or conventional systemic drug. Following outcomes are observed: Effectiveness on the long-term, of combined/alternating treatments and under comorbidity conditions; patient-defined benefits and quality of life, maintenance dosages, prediction of response and safety.
The study evaluates the long-term course of patients with Pso and PsA in systemic treatments. A patient will be included at first initiation of the treatment and will remain in the registry for 5 years, regardless of subsequent therapy. Nationwide, initially 35 (long-term approx. 50-80) dermatologic practices and hospital ambulances with expertise in systemic and biologic treatment will consecutively enroll patients. Follow-ups will be every 3 months, comprising patient and treatment characteristics, clinical parameters, patient-defined benefit, quality of life and adverse events. Standardized questionnaires will be addressed to the patient and to the dermatologist 12 times at the dermatologic centres. In interim intervals, patients are directly contacted another 9 times by mail.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Aarau, Switzerland, CH-5001
- Recruiting
- Aarau Cantonal Hospital
-
Contact:
- Marcus Streit, Dr. med.
- Phone Number: 062 838 68 38
- Email: markus.streit@ksa.ch
-
Principal Investigator:
- Marcus Streit, Dr. med.
-
Basel, Switzerland, CH-4031
- Recruiting
- Basel university hospital
-
Contact:
- Alexander Navarini, Prof.
- Email: Alexander.Navarini@usb.ch
-
Principal Investigator:
- Alexander Navarini, Prof.
-
Bern, Switzerland, CH-3001
- Recruiting
- Inselspital - Bern University Hospital
-
Contact:
- Luca Borradori, Prof.
- Phone Number: 031 632 2111
- Email: Luca.Borradori@insel.ch
-
Contact:
- Nikhil Yawalkar, Prof.
-
Principal Investigator:
- Nikhil Yawalkar, Prof.
-
Lausanne, Switzerland, CH-1011
- Recruiting
- Centre Hospitalier Universitaire Vaudois (Chuv)
-
Contact:
- Michel Gilliet, Prof.
- Email: michel.gilliet@chuv.ch
-
Principal Investigator:
- Curdin Conrad, PD Dr. med.
-
St. Gallen, Switzerland, CH-9007
- Recruiting
- St. Gallen Cantonal Hospital
-
Contact:
- Antonio Cozzio, Prof.
- Email: Antonio.Cozzio@kssg.ch
-
Principal Investigator:
- Antonio Cozzio, Prof.
-
Zurich, Switzerland, CH-8091
- Recruiting
- Zurich University Hospital
-
Contact:
- Tatjana Maul, PD Dr.
- Email: Julia-Tatjana.Maul@usz.ch
-
Principal Investigator:
- Tatjana Maul, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist,
- age ≥ 18,
- Being administered a specific biologic/conventional systemic drug for the first time
- Sufficient language skills (German, French, Italian and English) for the informed consent to participate
- Informed consent to participate
Exclusion Criteria:
- Lack of informed consent
- Patients being participants of clinical trials at the day of registration to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analyzed separately)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Methotrexate
Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
|
Cyclosporine A
Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
|
Etanercept
Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
Other Names:
|
Infliximab
Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
Other Names:
|
Adalimumab
Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
Other Names:
|
Ustekinumab
Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
Other Names:
|
Fumaric acids
Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
|
Other anti-psoriatic systemic treatments
e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
|
all dosages, frequencies and durations prescribed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psoriasis Area Severity Index (PASI)
Time Frame: every 6 months for 10 years
|
To evaluate clinical outcome of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
|
every 6 months for 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dermatology Life Quality Index (DLQI)
Time Frame: every 6 months for 10 years
|
To evaluate health related quality of life of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
|
every 6 months for 10 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse and serious adverse events
Time Frame: 10 years
|
Risk for adverse events and serious adverse events for patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis
|
10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alexander Navarini, Prof Dr med, Swiss Society of Dermatology and Venereology (SSDV)
- Principal Investigator: Julia-Tatjana Maul, PD Dr med, Swiss Society of Dermatology and Venereology (SSDV)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Dermatologic Agents
- Antifungal Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Etanercept
- Adalimumab
- Methotrexate
- Infliximab
- Cyclosporine
- Cyclosporins
- Ustekinumab
Other Study ID Numbers
- IMM 10-0138; P21007224R
- CNTO1275PSO4028; AG110401-IIR (Other Grant/Funding Number: AbbVie, Janssen Pharmaceutica, Novartis, Eli Lilly, Amgen)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Adalimumab
-
PfizerCompletedHealthyUnited States, Belgium
-
PfizerCompletedHealthy SubjectsUnited States
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Shanghai Henlius BiotechCompleted
-
AbbottCompleted
-
Turgut İlaçları A.Ş.CompletedHealthy ParticipantsGermany
-
Mylan Inc.Mylan GmbHCompletedPsoriasis | Arthritis, PsoriaticBulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
-
AbbottCompletedRheumatoid ArthritisSpain
-
AbbVie (prior sponsor, Abbott)CompletedRheumatoid ArthritisUnited States